Torrent Pharma Signs Agreement To Acquire Three Anti-Diabetics Brand
Torrent Pharmaceuticals Ltd. has signed an agreement with Boehringer Ingelheim International to acquire three anti-diabetes brands: Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin), and Xilingio (empagliflozin + linagliptin).
The acquisition will be completed by March 2025, according to an exchange filing. Torrent has promoted these brands since 2022 under a co-marketing agreement with Boehringer Ingelheim India.
Empagliflozin is an SGLT-2 inhibitor that helps control blood sugar in adults with type 2 diabetes. The market for SGLT-2 inhibitors is worth Rs 3,235 crore and has a growth rate of 25% per year.
“As we continue to strengthen our diabetes care portfolio, we will ensure continued access to the treatment for patients whilst building on our presence in the Oral Anti Diabetic market,” said Aman Mehta, director at Torrent Pharma.
According to the International Diabetes Federation, India has the second-largest number of diabetes patients in the world, with an estimated 74.2 million adults living with diabetes in 2021, according to the filing.
This number is expected to rise to nearly 125 million by 2045.
As per the Advanced Working, Action and Correction System or AWACS data from October 2024, the Indian diabetes medication market is valued at Rs 19,912 crore, growing at a rate of 7.7% per year over the past four years, it said.
The share price of Torrent Pharmaceuticals closed at Rs 3,352.65 per share on the National Stock Exchange, reflecting a decline of 0.31%. In contrast, the benchmark Nifty saw a slight increase of 0.04%.
Over the past 12 months, the stock has decreased by 57.14%, and it has fallen 35.42% year-to-date.
Among the 32 analysts monitoring the company, 19 have assigned a 'buy' rating to the stock, eight recommend a 'hold,' and five have given it a 'sell' rating, according to Bloomberg data. The average 12-month price targets from analysts suggest a potential upside of 6.6%.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.